Currently available hypolipidaemic drugs and future therapeutic developments

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Lipidology

Background:

• Dyslipidemia, a major risk factor for cardiovascular disease, necessitates effective pharmacological interventions.
• A variety of drug classes target distinct lipid abnormalities through diverse mechanisms.

Purpose of the Study:

• To review the mechanisms of action for key pharmacological agents used in dyslipidemia management.
• To summarize the safety profiles and potential adverse effects associated with these lipid-lowering drugs.

Main Methods:

• Review of pharmacological agents for dyslipidemia, including bile-acid sequestrants, nicotinic acid, HMG-CoA reductase inhibitors, fibric acid derivatives, and probucol.
• Analysis of their mechanisms of action on lipid metabolism.
• Compilation of reported adverse effects from clinical trials and literature.

Main Results:

• Bile-acid sequestrants decrease LDL cholesterol by binding bile acids.
• Nicotinic acid and HMG-CoA reductase inhibitors lower LDL cholesterol and triglycerides through different pathways.
• Fibric acid derivatives primarily reduce triglycerides, while probucol lowers LDL cholesterol and offers antioxidant properties.
• All agents have associated adverse effects, ranging from gastrointestinal issues to more severe complications like myolysis and hepatotoxicity.

Conclusions:

• Pharmacological agents offer safe and effective treatment options for various dyslipidemias.
• Understanding the specific mechanisms and potential adverse effects is crucial for optimizing therapeutic strategies and patient safety.
• Careful patient selection and monitoring are essential to mitigate risks associated with these lipid-modifying therapies.